Sixth Element leads £4m series-A for Azeria

The company plans to use the fresh capital to further develop its drug discovery programme and advance its research towards clinical trials.

Sixth Element deployed capital from its £70m CRT Pioneer Fund, which makes investments in companies engaged in drug discovery and clinical developments in the field of cancer. The vehicle was launched in 2012 and is backed by the European Investment Fund and the UK's Cancer Research Technology.

Company
Azeria was established in 2017 by Sixth Element Capital and Cancer Research UK. The company is based in Cambridge and specialises in developing breakthrough treatments for hormone-resistant breast and prostate cancer patients.

Using its proprietary drug screening platform, Azeria is developing a pipeline of small molecules designed to selectively inhibit pioneer factors shown to be pivotal in tumor development and which underpin drug resistance in cancer.

People
Azeria Therapeutics – Jason Carroll (founder, chief scientific officer).
Sixth Element Capital – Stephen Myatt (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• Venture
• United Kingdom